3-benzyloxycarbonylamino-4,4-dimethylpentanoic acid | 200642-84-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-benzyloxycarbonylamino-4,4-dimethylpentanoic acid
• 英文别名: Cbz-β(3)-neopentylglycine；3-[[(phenylmethoxy)carbonyl]amino]-4,4-dimethylpentanoic acid；3-(Benzyloxycarbonylamino)-4,4-dimethylpentanoic acid；4,4-dimethyl-3-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 200642-84-8
• 化学式: C₁₅H₂₁NO₄
• 分子量: 279.336
• InChiKey: PAENHBDXAWYRRZ-UHFFFAOYSA-N

物化性质

• 沸点：
  451.6±38.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  3-benzyloxycarbonylamino-4,4-dimethylpentanoic acid 生成 [3-[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-3-oxo-1-(1,1-dimethylethyl)propyl]carbamic acid phenylmethyl ester
  参考文献：
  名称：

  Thiadiazole amide MMP inhibitors

  摘要：

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。

  公开号：

  US05830869A1
• 作为产物：
  描述：

  氯甲酸苄酯 、 3-氨基-4,4-二甲基-戊酸 在 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 以77.6%的产率得到3-benzyloxycarbonylamino-4,4-dimethylpentanoic acid
  参考文献：
  名称：

  Enantiopure β3-neopentylglycine: synthesis and resolution

  摘要：

  A procedure has been developed for the large scale synthesis of enantiopure beta(3)-neopentylglycine and its Cbz-protected derivative. The synthetic route developed in Out laboratory features Cbz-protection of the racemic beta-amino acid followed by resolution with L-norephedrine and provides the enantiomerically Pure Cbz-beta-neopentylglycine in good yield and excellent enantiopurity. No toxic or dangerous chemicals are used, allowing the scale-up of this procedure without major safety concerns. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.01.018

文献信息

• THIADIAZOLE AMIDE MMP INHIBITORS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1021424B1

  公开（公告）日：2003-02-26
• [EN] THIADIAZOLE AMIDE MMP INHIBITORS<br/>[FR] INHIBITEURS THIADIAZOLE AMIDE DE LA METALLOPROTEASE
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1997048688A1

  公开（公告）日：1997-12-24

  (EN) The present invention provides novel thiadiazole amide derivatives represented by formula (I). The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.(FR) L'invention concerne de nouveaux dérivés thiadiazole amide représentés par la formule (I). Les composés décrits inhibent divers enzymes de la famille de la métalloprotéase matricielle (stromélysines essentiellement), d'où leur utilité pour le traitement des maladies liées à la métalloendoprotéase matricielle, par exemple: arthrose, polyarthrite chronique évolutive, arthrite aiguë suppurée, ostéopénies comme l'ostéoporose, métastase tumorale (invasion et croissance), parodontite, gingivite, ulcération cornéenne, ulcération cutanée, ulcération gastrique, inflammation et autres maladies inhérentes à la dégradation du tissu conjonctif.
• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• Enantiopure β3-neopentylglycine: synthesis and resolution
  作者：Matthijs K.J. ter Wiel、Mirjam Arnold、Sandra Peter、Ingo Troltsch、Stefan Merget、Florian Glaser、Michael Schwarm、Harjinder S. Bhatti、Biju Kuriakose、Suryakant S. Pol、Mohanasundaram Balamurugan、Viral V. Joshi

  DOI：10.1016/j.tetasy.2009.01.018

  日期：2009.3

  A procedure has been developed for the large scale synthesis of enantiopure beta(3)-neopentylglycine and its Cbz-protected derivative. The synthetic route developed in Out laboratory features Cbz-protection of the racemic beta-amino acid followed by resolution with L-norephedrine and provides the enantiomerically Pure Cbz-beta-neopentylglycine in good yield and excellent enantiopurity. No toxic or dangerous chemicals are used, allowing the scale-up of this procedure without major safety concerns. (c) 2009 Elsevier Ltd. All rights reserved.